Pilot Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma

Trial Profile

Pilot Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Hu3F8 (Primary) ; Granulocyte macrophage colony stimulating factor; Irinotecan; Temozolomide
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top